EVAX · Evaxion Biotech
AI read · Neutral
The AI's read
Evaxion reported a solid Q2: net loss $3.7M, $14M cash, runway into H2 2027, plus progress on EVX01 and new EVX05 glioblastoma work and AI recognition. Management flagged regulatory and first-in-human updates later this year which matter for valuation. The market already chewed through the headline. EVAX is up ~8.9% today and RSI sits at 75, so sentiment is stretched and some upside looks priced. Bottom line: good company-specific news but not a clean entry signal right now. We lean neutral until clinical/regulatory catalysts or clearer financing lower execution risk.